header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

PERCUTANEOUS TREATMENT IN PATIENTS WITH OSTEOID OSTEOMA BY RADIOFREQUENCY THERMAL ABLATION IMPROVE QUALITY OF LIFE, PAIN AND ANXIETY



Abstract

Purpose: The relationship between pain, quality of life (QOL) anxiety and depression in patients with chronic pain is complex. The aim of this study was focused in osteoid osteomas which treated with Radiofrequency thermal ablation (RFTA).

Patients and Methods: We determine the pain characteristics severity, duration, meaning of pain, (MINESOTA score), psychological distress (HADS), physical functioning, social functioning and quality of life (SF −36) and determine which of these variables improved after Radiofrequency thermal ablation in osteoid osteomas. A total of 26 patients with osteoid osteoma which proceed in RFTA and completed the questionnaires, evaluated pain, quality of life, anxiety, depression, physical functioning, and social functioning before and after the procedure in a mean follow up of 17 months. Pearson correlation coefficients were calculated to examine the relationships among the study variables. A multiple regression analysis was performed to determine which variables were the most important predictors.

Results: Pain was significantly correlated with all the other variables, in particular depression and anxiety. Pain QuoL and Depression improved dramatically after kyphoplasties in a follow up of 17 months period.

Conclusion: The clinical results indicate a 100% success rate with complete remission of symptoms and no relapses having been reported at the time of those patients who have arrived at the one year follow up. CT-guided RF ablation is a safe, simple and effective method of treatment for osteoid osteoma. and improve quality of life, anxiety and depression in these patients.

Correspondence should be addressed to: EFORT Central Office, Technoparkstrasse 1, CH – 8005 Zürich, Switzerland. Tel: +41 44 448 44 00; Email: office@efort.org

Author: Charalampos Matzaroglou, Greece

E-mail: orthopatras@yahoo.gr